ArticleInflammopharmacology2026
Integrated GC-MS phytochemical analysis and in vivo assessment of antiarthritic activity of Curcuma zedoaria extracts.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCurcuma zedoaria has been traditionally used to treat inflammatory conditions; however, comprehensive evaluation of its various solvent extracts, particularly in chronic arthritis models, remains limited. The research focused on assessing and comparing the antiarthritic potential of three Curcuma zedoaria extracts: CZC (chloroform extract), CZCM (chloroform–methanol, 1:1 extract), and CZM (methanol extract) to determine the most effective extract for mitigating chronic inflammation utilizing the Complete Freund’s Adjuvant (CFA)-induced arthritis model. MATERIALS AND
methodsGas chromatography-mass spectrometry (GC–MS) was conducted to examine the phytochemical profile. Acute analgesic models and anti-inflammatory models were employed to evaluate efficacy. Based on these results, the chloroform methanolic extract (CZCM) was selected for chronic evaluation in CFA-induced arthritic mice at dosages of 100, 200, and 400 mg/kg. Behavioral assessments, paw thickness, arthritis scoring, hematological and biochemical parameters, radiographic and histopathological analyses, and antioxidant enzyme assays (SOD, CAT, GSH, POD, GST, TBARS, NO) were conducted over 21 days.
resultsCZCM exhibited the most potent analgesic and anti-inflammatory activity in acute models. In chronic arthritis testing, it dose-dependently improved pain thresholds, reduced paw swelling and arthritis scores, and normalized hematological and biochemical biomarkers. Radiological and histopathological findings confirmed joint preservation. These therapeutic effects were primarily attributed to curcuminoids and sesquiterpenes identified via GC–MS analysis, aligning with known bioactivities of Curcuma species.
conclusionsThe chloroform-methanolic extract of Curcuma zedoaria (CZCM) demonstrated strong antiarthritic, antioxidative, and anti-inflammatory activities, suggesting it as a promising candidate for modifying disease progression in rheumatoid arthritis. Further studies are needed to isolate active phytoconstituents and explore clinical applicability.
Indexed as
Identifiers
41870771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.